News - Pfizer, Lipitor


Current filters:


Popular Filters

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia


The Australian Competition and Consumer Commission revealed today that is has instituted proceedings…

Asia-PacificAustraliaCardio-vascularLegalLipitorMarkets & MarketingPfizerPharmaceutical

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins


New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Pfizer revenues down as patent losses hit sales

Pfizer revenues down as patent losses hit sales


Global pharma giant Pfizer has said worldwide sales fell 2% to $12.6 billion, hurt by generic competition,…

AriceptEliquisEnbrelFinancialLipitorNorth AmericaPfizerPharmaceuticalRebifSpiriva

$30 billion of fresh opportunities for Rx-to-OTC switch in USA


The US Food and Drug Administration has recently created the Non-prescription Safe Use Regulatory Expansion…

LipitorMarkets & MarketingNorth AmericaPfizerPharmaceuticalRegulation

Ranbaxy debuts generic Lipitor in Germany, ahead of patent expiry


The German subsidiary of India's Ranbaxy Laboratories (AB: BO), Basics GmbH located in Leverkusen, yesterday…

atorvastatinBasics GmbHCardio-vascularDaiichi SankyoEuropeGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

FDA expands on cholesterol-lowering drug risks


Important safety changes to the labeling for some widely used cholesterol-lowering drugs known as statins…

AstraZenecaCardio-vascularCrestorLipitorMerck & CoNorth AmericaPfizerPharmaceuticalRegulationZocor

Lipitor and strategic collapse at Pfizer, a consultants view


Now global pharma behemoth Pfizer (NYSE: PFE) spent $114 billion in 2000 for a hostile takeover of Warner-Lambert,…

Cardio-vascularFinancialLipitorMarkets & MarketingPfizerPharmaceutical

Payers’ outlook for Pfizer’s Lipitor generic strategy not rosy; second Caduet copy launched by Ranbaxy


Reimbursement Intelligence, a USA-based market-research firm, has announced how payers predict the impact…

CaduetCardio-vascularGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

US launch of generic Lipitor confirms value of competition, says GPhA


Commenting on this week’s US roll out for generic copies of Pfizer blockbuster cholesterol lowerer…

GenericsLipitorMarkets & MarketingNorth AmericaPatentsPfizerRanbaxy LaboratoriesWatson Pharmaceuticals

Mixed results for AstraZeneca in study comparing Crestor with Lipitor


Anglo-Swedish drug major AstraZeneca (LSE: AZN) presented mixed results from a study comparing its cholesterol…


AstraZeneca launches new Crestor savings card in USA, as generic Lipitor about to debut


The US subsidiary of Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday launched a new savings…

AstraZenecaCardio-vascularCrestorGenericsLipitorNorth AmericaPfizerPharmaceuticalPricing

AstraZeneca’s Crestor fails to show significant improvement over Lipitor


There was a big disappointment for Anglo-Swedish drug major AstraZeneca (LSE: AZN) on Friday, when it…


Pfizer in generic Lipitor deals with Sanofi and Dr Reddy’s


Global drugs behemoth Pfizer (NYSE: PFE) has reached agreement with French drug major Sanofi (Euronext:…

atorvastatinCardio-vascularDr Reddy's LaboratoriesGenericsLegalLicensingLipitorPfizerSanofiZentiva

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top